In vivo anti-tumor effect of expressing p14ARF-TAT using a FGF2-targeted cationic lipid vector

Pharmaceutical Research

Volumn 28, Issue 4, 2011, Pages 720-730

  Niu, Guoqin ^a   Driessen, Wouter H P ^a,b   Sullivan, Sean M ^c   Hughes, Jeffrey A ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VICAL INC   (United States)

^d NONE   (United States)

Author keywords

anti tumor effect; cationic liposome; fibroblast growth factor (FGF2); fusion cytotoxic gene; lipid based gene delivery

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FIBROBLAST GROWTH FACTOR 2; KANAMYCIN; LIPOPLEX; LUCIFERASE; METHYLVALYLARGINYLARGINYLPHENYLALANYLLEUCYLVALYLTHREONYLLEUCYLARGINYLISOLEUCYLARGINYLARGINYLALANINE TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CATIONS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; FIBROBLAST GROWTH FACTOR 2; GENE PRODUCTS, TAT; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; LUCIFERASES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; PLASMIDS; POLYETHYLENE GLYCOLS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 79955623588     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0353-x     Document Type: Article

References (42)

1. ML Edelstein MR Abedi J Wixon RM Edelstein 2004 Gene therapy clinical trials worldwide 1989-2004-an overview J Gene Med 6 597 602 15170730 10.1002/jgm.619 (Pubitemid 40228075)
2. J Gomez-Navarro DT Curiel 2000 Conditionally replicative adenoviral vectors for cancer gene therapy Lancet Oncol 1 148 158 11905653 10.1016/S1470-2045(00)00030-9 1:CAS:528:DC%2BD3MXhsFGjsLg%3D
3. PR Clark EM Hersh 1999 Cationic lipid-mediated gene transfer: current concepts Curr Opin Mol Ther 1 158 176 11715940 1:CAS:528:DyaK1MXjslCntL0%3D (Pubitemid 29238421)
4. BA Sosnowski DL Gu M D'Andrea J Doukas GF Pierce 1999 FGF2-targeted adenoviral vectors for systemic and local disease Curr Opin Mol Ther 1 573 579 11249664 1:CAS:528:DC%2BD3cXit1Gltg%3D%3D (Pubitemid 29522881)
5. LA Chandler BA Sosnowski L Greenlees SL Aukerman A Baird GF Pierce 1999 Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines Int J Cancer 81 451 458 10209961 10.1002/(SICI)1097- 0215(19990505)81:3<451::AID-IJC20>3.0.CO;2-H 1:CAS:528:DyaK1MXisVKhsLk%3D (Pubitemid 29165205)
6. H Kobayashi H Sakahara M Hosono M Shirato J Konishi JA Takahashi Y Oda H Kikuchi K Endo Y Kozai, et al. 1993 Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor Cancer Immunol Immunother 37 5 281 285 8402731 10.1007/BF01518449 1:STN:280:DyaK2c%2Fgs1emtg%3D%3D (Pubitemid 23300510)
7. K Kono T Ueba JA Takahashi N Murai N Hashimoto A Myoumoto N Itoh M Fukumoto 2003 In vitro growth suppression of human glioma cells by a 16-mer oligopeptide: a potential new treatment modality for malignant glioma J Neurooncol 63 2 163 171 12825820 10.1023/A:1023908307863 (Pubitemid 36705685)
8. C Trudel V Faure-Desire RZ Florkiewicz A Baird 2000 Translocation of FGF2 to the cell surface without release into conditioned media J Cell Physiol 185 2 260 268 11025448 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X 1:CAS:528:DC%2BD3cXntVygsb4%3D
9. AC Stan MN Nemati T Pietsch GF Walter H Dietz 1995 In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor J Neurosurg 82 1044 1052 7539064 10.3171/jns.1995.82.6.1044 1:STN:280:DyaK2M3otVWgtQ%3D%3D
10. PR Murphy Y Sato RS Knee 1992 Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line Mol Endocrinol 6 6 877 884 1323055 10.1210/me.6.6.877 1:CAS:528:DyaK38Xks1Olsb0%3D
11. C Basilico D Moscatelli 1992 The FGF family of growth-factors and oncogenes Adv Cancer Res 59 115 165 1381547 10.1016/S0065-230X(08)60305-X 1:CAS:528:DyaK3sXntlOhuw%3D%3D
12. T Kurokawa R Sasada M Iwane K Igarashi 1987 Cloning and expression of cDNA encoding human basic fibroblast growth factor FEBS Lett 213 189 194 2435575 10.1016/0014-5793(87)81489-8 1:CAS:528:DyaL2sXktlChurg%3D (Pubitemid 17036151)
13. F Maruta AL Parker KD Fisher MT Hallissey T Ismail DC Rowlands, et al. 2002 Identification of FGF receptor-binding peptides for cancer gene therapy Cancer Gene Ther 9 6 543 552 12032665 10.1038/sj.cgt.7700470 1:CAS:528:DC%2BD38XksVGhtr4%3D (Pubitemid 34569037)
14. GA Rao R Tsai D Roura JA Hughes 2008 Evaluation of the transfection property of a peptide ligand for the fibroblast growth factor receptor as part of PEGylated polyethylenimine polyplex J Drug Target 16 1 79 89 18172824 10.1080/10611860701733328 1:CAS:528:DC%2BD1cXht1yktQ%3D%3D
15. JW Izard DA Kendall 1994 Signal peptides: exquisitely designed transport promoters Mol Microbiol 13 765 773 7815936 10.1111/j.1365-2958.1994.tb00469.x 1:CAS:528:DyaK2cXmsVyksrw%3D (Pubitemid 24272197)
16. E Vives JP Richard C Rispa B Lebleu 2003 TAT peptide internalization: seeking the mechanism of entry Curr Protein Pept Sci 4 125 132 12678851 10.2174/1389203033487306 1:CAS:528:DC%2BD3sXitlSrt7g%3D (Pubitemid 36834011)
17. SR Schwarze A Ho A Vocero-Akbani SF Dowdy 1999 In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1569 1572 10477521 10.1126/science.285.5433.1569 1:CAS:528: DyaK1MXlslOru78%3D (Pubitemid 29420581)
18. JP Richard K Melikov E Vives C Ramos B Verbeure MJ Gait, et al. 2003 Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake J Biol Chem 278 585 590 12411431 10.1074/jbc.M209548200 1:CAS:528: DC%2BD38XpvVWnsrk%3D (Pubitemid 36043612)
19. SP Deb 2003 Cell cycle regulatory functions of the human oncoprotein MDM2 Mol Cancer Res 1 1009 1016 14707284 1:CAS:528:DC%2BD2cXns1Gk (Pubitemid 38044976)
20. T Buschmann T Minamoto N Wagle SY Fuchs V Adler M Mai Z Ronai 2000 Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability J Mol Biol 295 4 1009 1021 10656807 10.1006/jmbi.1999.3387 1:CAS:528:DC%2BD3cXot12rsQ%3D%3D
21. p19ARF links the tumour suppressor p53 to Ras. Palmero I, Pantoja C, Serrano M. Nature. 1998;395(6698):125-6. (Pubitemid 28425643)
22. YP Jarajapu J Baltunis HJ Knot SM Sullivan 2005 Biological evaluation of penetration domain and killing domain peptides J Gene Med 7 908 917 15832372 10.1002/jgm.738 1:CAS:528:DC%2BD2MXos1aqsrs%3D (Pubitemid 41015539)
23. JF Baskar PP Smith G Nilaver RA Jupp S Hoffmann NJ Peffer DJ Tenney AM Colberg-Poley P Ghazal JA Nelson 1996 The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice J Virol 70 5 3207 3214 8627801 1:CAS:528:DyaK28Xit1Ogsrs%3D (Pubitemid 26121939)
24. M Robert-Guroff M Popovic S Gartner P Markham RC Gallo MS Reitz 1990 Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages J Virol 64 3391 3398 2191150 1:CAS:528:DyaK3cXkslajt78%3D (Pubitemid 20219544)
25. MI Gyongyossy-Issa W Muller DV Devine 1998 The covalent coupling of Arg-Gly-Asp-containing peptides to liposomes: purification and biochemical function of the lipopeptide Arch Biochem Biophys 353 101 108 9578605 10.1006/abbi.1998.0623 1:CAS:528:DyaK1cXjtF2ksbc%3D (Pubitemid 28373034)
26. BA Sosnowski AM Gonzalez LA Chandler YJ Buechler GF Pierce A Baird 1996 Targeting DNA to cells with basic fibroblast growth factor (FGF2) J Biol Chem 271 33647 33653 8969234 10.1074/jbc.271.52.33647 1:CAS:528:DyaK2sXit12msQ%3D%3D (Pubitemid 27010184)
27. D Li H Yu H Huang F Shen X Wu J Li, et al. 2007 FGF receptor-mediated gene delivery using ligands coupled to polyethylenimine J Biomater Appl 22 163 180 17255154 10.1177/0885328206074503 1:CAS:528:DC%2BD2sXhtFGgtbjJ (Pubitemid 351193497)
28. WH Driessen N Fujii H Tamamura SM Sullivan 2008 Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells Mol Ther 16 516 524 18195720 10.1038/sj.mt.6300388 1:CAS:528:DC%2BD1cXisFOku78%3D (Pubitemid 351314991)
29. Li S, Driessen WH, Sullivan SM and Jiang H. Bioluminescence tomography based on phantoms with different concentrations of bioluminescent cancer cells. J Opt A: Pure Appl. 2006;743-6. (Pubitemid 44523070)
30. L Peeters NN Sanders A Jones J Demeester SC De Smedt 2007 Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells J Contr Release 121 207 217
31. A Krishnadas I Rubinstein H Onyüksel 2003 Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs Pharm Res 20 297 302 12636171 10.1023/A:1022243709003 1:CAS:528:DC%2BD3sXpslWhsQ%3D%3D (Pubitemid 36269739)
32. MM Tomayko CP Reynolds 1989 Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 24 3 148 154 2544306 10.1007/BF00300234 1:STN:280:DyaL1M3ovVGjug%3D%3D (Pubitemid 19163397)
33. T Struchbury M Shipton R Norris JPG Malthouse K Brocklehurst 1975 Reporter group delivery system with both absolute and select ive specificity for thiol groups and an improved fluorescent probe containing the 7-nitrobenzo-2-oxa-1.3-diazole moiety Biochem J 151 417 432
34. S Li FC MacLaughlin JG Fewell Y Li V Mehta MF French JL Nordstrom M Coleman NS Belagali RJ Schwartz LC Smith 1999 Increased levels and duration of expression in muscle by co-expression of a transactivator using plasmid systems Gene Ther 6 2005 2011 10637452 10.1038/sj.gt.3301032 1:CAS:528: DC%2BD3cXhslajsg%3D%3D (Pubitemid 30076871)
35. LY Song QF Ahkong Q Rong Z Wang S Ansell MJ Hope B Mui 2002 Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes Biochim Biophys Acta 1558 1 1 13 11750259 10.1016/S0005-2736(01)00399- 6 1:CAS:528:DC%2BD3MXptFymsrk%3D (Pubitemid 34031950)
36. L Cao J Si W Wang X Zhao X Yuan H Zhu X Wu J Zhu G Shen 2006 Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells Mol Cells 21 1 104 111 16511352
37. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010 May 2. [Epub ahead of print].
38. LC Shaw H Pan A Afzal S Li Calzi PE Spoerri SM Sullivan MB Grant 2006 Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization Gene Ther 13 752 760 16437130 10.1038/sj.gt.3302718 1:CAS:528:DC%2BD28XjsFWju7Y%3D
39. JL Kielczewski YP Jarajapu EL McFarland J Cai A Afzal S Li Calzi KH Chang T Lydic LC Shaw J Busik J Hughes AJ Cardounel K Wilson TJ Lyons ME Boulton RN Mames T Chan-Ling MB Grant 2009 Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation Circ Res 105 9 897 905 19762684 10.1161/CIRCRESAHA.109.199059 1:CAS:528:DC%2BD1MXhsVCiurrE
40. CH Choi CA Alabi P Webster ME Davis 2010 Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc Natl Acad Sci USA 107 3 1235 1240 20080552 10.1073/pnas.0914140107 1:CAS:528: DC%2BC3cXht1Srt7Y%3D
41. G Niu CH Castro N Nguyen SM Sullivan JA Hughes 2010 In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells J Drug Target 18 6 468 476 20059301 10.3109/10611860903508804 1:CAS:528:DC%2BC3cXntVagtbg%3D
42. S Rudginsky W Siders L Ingram J Marshall R Scheule J Kaplan 2001 Antitumor activity of cationic lipid complexed with immunostimulatory DNA Mol Ther 4 4 347 355 11592838 10.1006/mthe.2001.0463 1:CAS:528:DC%2BD38XhvFGqt7s%3D (Pubitemid 33040520)